Awards Given to CPCR Investigators


Investigators in the David M. Rubenstein Center for Pancreatic Cancer Research (CPCR) have been recognized with major funding from sources outside Memorial Sloan Kettering Cancer Center — an acknowledgement of the importance of their work.

Among those funding sources:

Specialized Program of Research Excellence (SPORE) in Pancreatic Cancer

MSK achieved a new level of distinction in 2022, becoming only the fourth institution in the country to receive funding as a Specialized Program of Research Excellence (SPORE) in pancreatic cancer. SPORE grants are a centerpiece of the National Cancer Institute’s promotion of collaborative translational cancer research. They emphasize work that stands to meaningfully impact clinical practice in the near future.

Co-led by Eileen O’Reilly, MD, and Christine Iacobuzio-Donahue, MD, PhD, in collaboration with a multidisciplinary research team, the MSK pancreatic cancer SPORE is focused on improving outcomes for people with locally advanced and metastatic pancreatic cancer — patients who have the fewest treatment options. More details on the SPORE can be found here:

Break Through Cancer

Break Through Cancer (BTC), a foundation that supports groundbreaking cancer research, is creating a series of transformative projects run out of collaborative “TeamLabs.” These groups are designed to change the story — catalyzing new, highly effective therapies that reach patients quickly. CPCR investigators are involved in two BTC-funded projects. Details on BTC Pancreatic Cancer Projects can be found here: